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We have studied the long-term prognosis of 266 patients considered to have isolated local recurrence in the breast following con-
servative surgery and radiotherapy for early breast cancer. The median follow-up of the patients still alive after diagnosis of local
relapse was 11.2 years. At 10 years from the date of salvage treatment, the overall survival rate for the 226 patients with invasive local
recurrence was 39% (95%CI, 32–46), the distant recurrence-free survival rate was 36% (95%CI, 29–42), and the local control rate (i.e.,
survival without subsequent local recurrence or local progression) was 68% (95% CI, 62–75). Among patients with a local recurrence
at or near the original tumour site a better distant disease-free survival was observed for patients with recurrences measuring 1 cm or
less, compared to those with larger recurrences. This suggests, though does not prove, that early detection of local recurrence can
improve the treatment outcome but might as well point towards a different biologic behaviour, facilitating early detection.
 2005 Elsevier Ltd. All rights reserved.
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It is estimated that each year about 300,000 women
with stages I and II breast cancer undergo breast-con-
serving therapy (BCT) worldwide [1]. Rates of local
recurrence in the preserved breast vary between 2%
and 10% after 5 years and between 5% and 15% at 10
years [1–10]. Considering the growing number of pa-
tients who have undergone BCT and the risk of local
recurrence also extending after more than 10 years of
follow-up, the number of patients experiencing a local
recurrence is expected to increase considerably in the
future.
Whilst the poor prognosis of patients with a local
recurrence after modified radical mastectomy is well
established, there has been considerable debate about
the prognosis and salvage possibilities for patients with
local recurrence after BCT. Earlier studies reported
5-year survival rates ranging from 70% to 84% after sal-
vage treatment for patients with local recurrence after
BCT, which is equal or only slightly worse compared
with those without local recurrence [5,11–13]. More re-
cent series, however, reported poorer 5-year survival
rates, ranging from 55% to 68% after 5 years [3,14]
and one study even reached the conclusion that the sur-
vival after treatment for an early loco-regional recur-
rence after modified radical mastectomy or BCT is
similar [15]. The unfavourable prognostic effect of devel-
oping a local recurrence has been confirmed by other
studies, that included local recurrence in a multivariate
analysis as a time-dependent variable and showed it to
be a strong independent predictor of the risk of develop-
ing distant metastatic disease [6,7,16–21]. Figures on the
long-term prognosis of patients with local recurrence are
scarce and based on small patient series. Interpretation
and comparison of the results is also hampered by het-
erogeneity; some focused on prognosis after local recur-
rence treated with salvage mastectomy, whereas others
studied prognosis after all local recurrences regardless
of therapy. In some studies, patients were included
who also had distant metastasis diagnosed before or
simultaneously with local recurrence. Finally, studies
on prognostic factors for patients with local recurrence
made use of different end-points, some presenting over-
all survival and other distant disease-free or cause-spe-
cific survival.
This report describes the long-term prognosis of 266
patients with local recurrence after BCT as first event,
i.e., without clinical signs of distant metastases at the
time of diagnosis of local recurrence. In a previous re-
port, with a median follow-up time of 52 months, the
distant recurrence free survival rate for all 266 patients
was 61% (95% CI, 40–53%) at 5-years from the date of
salvage treatment [22]. At that time, the survival curve
showed no tendency of levelling off, indicating that dis-
tant recurrences continue to occur more than five yearsafter diagnosis of local recurrence. For the current
study, the median follow-up of the cohort has been ex-
tended to more than 11 years, which offered us the pos-
sibility to calculate the survival rates at 10 years after the
diagnosis of local recurrence and identify subgroups
with a good and a poor long-term prognosis.2. Patients and methods
2.1. Patients and data collection
Patient data were obtained from eight departments of
radiotherapy, two cancer institutes and one department
of surgery in the Netherlands, which maintained com-
plete records on approximately 7000 patients with inva-
sive breast cancer undergoing BCT. BCT generally
consisted of wide local excision of the tumour with an
attempted margin of at least 1 cm of healthy tissue
and axillary dissection, followed by 45–50 Gy whole
breast irradiation in fractions of 1.8 or 2.0 Gy five times
a week. An additional boost was given to the tumour
bed by an external beam technique, using either photons
or electrons, or by the use of iridium 192 interstitial im-
plants. Total boost doses varied between 15 and 25 Gy
but were sometimes higher for iridium 192 implants.
Adjuvant systemic therapy was given only to axillary
node-positive patients; in general premenopausal pa-
tients received 6 cycles of adjuvant cyclophosphamide,
methotrexate and 5-fluorouracil (CMF) combination
chemotherapy, given after the completion of radiother-
apy, whereas postmenopausal patients received 20 mg
of tamoxifen daily for at least 1 year.
Together, the participating centres identified 360 pa-
tients with local recurrence after BCT, diagnosed before
January 1994. Local recurrence was defined as a new tu-
mour occurring in the preserved breast or overlying skin
after complete loco-regional treatment. Of the 360 local
recurrences, 28 (8%) were detected after the diagnosis of
distant disease, and in 66 (18%) distant disease was diag-
nosed within three months after the diagnosis of local
recurrence. The remaining 266 patients (74%) showed
no signs of distant metastases or axillary recurrence, at
least within the first threemonths after the diagnosis of lo-
cal recurrence. These 266 patientswere considered to have
an isolated local recurrence and constitute the study pop-
ulation. Of these, 248 (93%) had undergone BCT during
the 1980s and 18 (7%) during the period 1990–1992. Three
patients had not received a boost dose. At initial diagno-
sis, 150 (56%) hadpathological stage I primary breast can-
cer (T1N0M0), 83 patients (31%) stage IIA (T1N1M0,
T2N0M0), 28 (11%) stage IIB (T3N0M0, T2N1M0) and
four (1%) stage IIIA (T3N1M0, T1–3N2M0). Axillary
lymph nodes were involved in 71 of the 266 patients
(27%) at the time of primary treatment. The median age
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local recurrence. The median time between the date of
breast-conservative surgery and diagnosis of local recur-
rence was 3.6 years (range: 0.3–13.1 years). Seventy-eight
recurrences (29%) occurred within two years of BCT, 127
(48%)between two andfive years, and 61 (23%)more than
five years after BCT.
Further details on collection of information on the
method of detection and the location, the extent, histo-
logic type and treatment of the local recurrence have
been described before [22]. Specimens of the primary tu-
mour were available for review for 238 of the 266 pa-
tients (89%). Follow-up of the patients was updated
until January 2003. The median follow-up time for sur-
viving patients after diagnosis of local recurrence was
134 months.
2.2. Statistical analysis
Survival analysis, using the life-table method, was
performed to evaluate the prognosis after local recur-
rence. End-points were overall survival, distant dis-
ease-free survival and survival without subsequent
local recurrence, including local progression of disease.
Survival curves were calculated from the date of salvage
treatment of local recurrence or the date of the diagnosis
of local recurrence when salvage treatment was not gi-
ven. The following variables were analysed to assess
their ability to predict distant recurrence-free survival:
age at diagnosis of local recurrence; time interval from
initial surgery to recurrence; mode of detection, loca-
tion, size and histologic type of local recurrence; size,
nodal status, histologic grade and microscopic margins
of the original tumour; and presence of vascular inva-
sion and extensive intraductal component (EIC) in the
original tumour. Actuarial curves were compared by
means of the two-tailed log-rank test. A multivariate
analysis using the Cox proportional hazards model
was performed to evaluate the independent predictive ef-
fect of the covariates. Hazard ratios (with 95% confi-
dence intervals (95% CI) and P values) were estimated
for each covariate in relation to the reference category.
As the prognostic effect of the co-variates is likely to
vary for patients with an early or a late local recurrence,
separate analyses were performed for the group with a
local recurrence within three years after diagnosis of
the primary tumour and the group with a recurrence-
free interval of more than three years after BCT.0
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Fig. 1. Distant-recurrence-free survival of 226 patients with invasive
local recurrence (LR) following breast-conserving therapy.3. Results
3.1. Diagnosis and treatment
Local recurrence was diagnosed by mammography
alone in 47 cases (25%), by physical examination (i.e.,on the basis of signs or symptoms) in 102 cases (54%)
and by both physical examination and mammography
in 40 cases (21%). 225 patients (85%) underwent salvage
mastectomy and 20 (8%) local excision, 11 (4%) only re-
ceived systemic treatment and 8 patients (3%) remained
untreated. Treatment was unknown for one patient. De-
tailed results on the detection and treatment of LR have
been described elsewhere [22].
3.2. Outcome
Of the 266 patients with local recurrence, 226 had an
invasive and 25 a non-invasive recurrence. Information
on the invasiveness of the recurrence was lacking for
15 patients. Of the 226 patients with invasive local recur-
rence 148 (65%) had died. Distant metastases were ob-
served in 145 patients (64%) and subsequent local
recurrence or local progression in 66 (31%). Of the 145
distant metastases, 88 (61%) were detected within 2.5
years after diagnosis of local recurrence, 126 (87%) oc-
curred within 5 years and 139 (96%) within 10 years.
At 10 years from the date of salvage treatment, the over-
all survival rate for the 226 patients with invasive local
recurrence was 39% (95% CI, 32–46), the distant recur-
rence-free survival rate was 36% (95% CI, 29–42), and
the local control rate (i.e., survival without subsequent
local recurrence or local progression) was 68% (95%
CI, 62–75) (Fig. 1).
Univariate analysis showed the following factors to
be significantly associated with the occurrence of distant
metastases following an invasive local recurrence: the
mode of detection, the type and size of local recurrence,
the axillary lymph node status of the primary tumour
and the presence of vascular invasion in the primary tu-
mour (Table 1). Patients with a local recurrence that had
been detected by mammography alone were less likely to
develop distant disease than those with a palpable recur-
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OTS, <1.0 cm (n=37) OTS, 1.1-3.0 cm (n=60)
elsewhere in breast (n=31) skin involvement (n=18)
OTS and >3.0 cm or diffuse (n=52)
Fig. 2. Distant-recurrence-free survival of 226 patients with invasive
local recurrence (LR) following breast-conserving therapy, according
to the type of LR (OTS: at or near the original tumour site).
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nosis of patients with a recurrence elsewhere in the
breast appeared to be similar to the prognosis of those
with a recurrence of 1 cm or less located at or near the
site of the original tumour and significantly better than
the prognosis of the patients with larger recurrences
(Fig. 2). A very poor prognosis was observed for pa-
tients with a recurrence involving the skin (Fig. 2).
The proportion of patients developing distant metasta-
ses varied between 62% and 78% in the five institutes
that contributed at least 25 patients with local recur-
rence to the study (P = 0.47).
Of the 25 patients with a non-invasive recurrence, 4
developed distant metastases and their time to distant
disease varied between 53 and 79 months.
The results of the multivariate Cox regression analyses
of prognostic factors for distant recurrence-free survival,
overall survival and local control are presented in Table 2.Table 1
Univariate analysis of factors related to distant recurrence in patients with invasive local recurrence after breast-conserving therapy (n = 226)
Variable No. of patients Distant recurrence-free survival
No. Five-year actuarial rate (SE) P-value (log-rank)
Age at diagnosis of LR (years)
<45 81 56 43 (5) 0.405
45–64 121 75 49 (4)
65 24 14 55 (9)
Time interval to LR (years)
2.0 68 45 43 (6) 0.746
2.1–5.0 107 69 39 (5)
>5.0 51 31 53 (7)
Mode of detection of LR
Mammography alone 38 20 58 (8) 0.038
Signs and symptoms 125 85 36 (4)
Type of LR
At or near OTS and 1.0 cm 37 15 63 (8) <0.0001
At or near OTS and 1.1–3.0 cm 60 40 40 (6)
Elsewhere in breast 31 14 60 (9)
At or near OTS and >3.0 cm or diffuse 52 38 35 (7)
Skin involvement 18 17 11 (7)
Lymph node status of primary tumour
Negative 173 105 48 (4) 0.020
Positive 53 40 29 (6)
Size primary tumour (cm)
2.0 169 109 44 (4) 0.997
>2.0 55 34 42 (7)
Vascular invasion (primary)
No 131 85 50 (4) 0.017
Yes 55 48 33 (6)
Extensive intraductal component (primary)
No 149 91 43 (4) 0.857
Yes 49 34 51 (7)
Histologic grade (primary)
Low/intermediate 90 53 49 (6) 0.339
High 120 72 43 (5)
Table 2
Cox regression analysis: distant recurrence, death, and subsequent local recurrence (LR) or local progression
Variable Distant recurrence Death Subsequent LR or local
progression
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Type of LR
At or near OTS and 1.0 cm 1 (Ref) 1 (Ref) 1 (Ref)
At or near OTS and 1.1–3.0 cm 1.86 1.15–3.00 0.012 1.70 1.06–2.74 0.028 1.56 0.73–3.32 0.247
At or near OTS and >3.0 cm or diffuse 2.53 1.55–4.15 0.0002 2.39 1.49–3.83 0.0003 2.17 1.23–3.82 0.007
Elsewhere in breast 1.04 0.49–2.19 0.218 0.90 1.30–6.03 0.775 1.52 0.48–4.81 0.478
Skin involvement 4.24 2.30–7.82 <0.0001 5.89 3.24–10.73 <0.0001 3. 56 1.67–7.63 0.001
Lymph node status of primary tumour
Negative 1 (Ref) 1 (Ref) 1 (Ref)
Positive 1.70 1.14–2.54 0.010 1.96 1.32–2.92 0.0009 1.68 0.94–2.99 0.08
HR: hazard ratio; OTS: original tumour site; CI: confidence interval.
A.C. Voogd et al. / European Journal of Cancer 41 (2005) 2637–2644 2641The following variables were included in the multivariate
model: age at diagnosis of local recurrence, time interval
to local recurrence, type of local recurrence and lymph
node status and size of the primary tumour. Due to miss-
ing information on one or more of these variables, 30 pa-
tients had to be excluded from the multivariate analyses.
The prognosis of these patients with respect to the three
end-points appeared to be similar to the prognosis for
the 196 left for the multivariate model, indicating that
there was not a selective drop-out of patients from the
multivariate analysis. The results of themultivariate anal-
yses showed only slight differences with respect to the
three end-points. Patients with positive axillary lymph
nodes at the time of diagnosis of the primary tumour
had a significantly higher risk of dying or developing dis-
tant disease, compared to patients with a negative lymph
node status. Patients with a local recurrence at or near the
original tumour site measuring 1.0 cm or less had a lower
risk of dying or developing distant disease compared to
patients with a larger recurrence. Skin involvement of lo-
cal recurrence was the strongest prognostic factor for the
occurrence of distant disease, subsequent local recurrenceTable 3
Cox regression analysis: distant recurrence, according to the time interval be
recurrence




At or near OTS and 1.0 cm 1 (Ref)
At or near OTS and 1.1–3.0 cm 1.83 0.88–3.81
At or near OTS and >3.0 cm or diffuse 1.92 1.06–3.48
Elsewhere in breast 0.62 0.18–2.10
Skin involvement 3.34 1.67–6.71
Lymph node status of primary tumour
Negative 1 (Ref)
Positive 1.88 1.05–3.34
HR: hazard ratio; OTS: original tumour site; CI: confidence interval.or local progression and for death. Adding vascular inva-
sion andmode of detection to themodel significantly low-
ered the statistical power of the model without improving
its prognostic value.
Multivariate analyses were also performed accord-
ing to the time to recurrence (Table 3). A positive
lymph node status of the primary tumour was signif-
icantly associated with an increased risk of developing
distant disease in patients with a local recurrence with-
in three years after BCT but not for patients with a
local recurrence more than three years after BCT.
For both early and late recurrences, a larger diameter
and involvement of the skin were unfavourable prog-
nostic factors, although the effect of the skin involve-
ment was only statistically significant for the early
recurrences.4. Discussion
The current study is one of the largest describing the
long-term prognosis of patients with recurrence in thetween the diagnosis of the primary tumour and the diagnosis of local
ary tumour and local recurrence
>3.0 years
P-value HR 95% CI P-value
1 (Ref)
0.109 1.93 1.06–3.50 0.032
0.032 2.32 1.19–4.52 0.014
0.443 1.53 0.52–4.50 0.441
0.0007 2.74 0.90–8.32 0.075
1 (Ref)
0.033 1.20 0.64–2.25 0.578
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two third ultimately develops distant metastases. Not
only the site of the recurrence but also its size provided
important information about the risk of developing dis-
tant disease. Patients with recurrences 61 cm had a
lower distant recurrence risk compared to patients with
local recurrences >1 cm. Although this seems to point
towards a potential benefit of early detection of local
recurrence, it can also be explained by a different biolog-
ical behaviour, associated with certain clinical and mam-
mographic features that facilitate detection. Prognostic
factors were almost similar for patients with a local
recurrence within three years after diagnosis of the pri-
mary tumour and the group with a recurrence-free inter-
val of more than three years, except for the axillary
nodal status of the primary tumour that was only of
importance for the first group.
Many studies have been performed to distinguish the
local recurrences associated with a good or a poor prog-
nosis and to identify risk factors for the development of
distant metastases. The question is whether salvage mas-
tectomy is sufficient treatment or should it be followed
by systemic treatment, depending on the risk for distant
relapse? There is currently no good evidence that adju-
vant systemic treatment is effective in patients with local
recurrence. In a recent Cochrane systematic review of
three randomised-controlled trials comparing systemic
therapy versus observation for women with loco-regio-
nal recurrence following mastectomy or breast-conserv-
ing treatment who did not have previous or synchronous
distant metastases, provided insufficient evidence for an
improvement in the overall survival [23]. However, when
overlooking the available evidence for its effectiveness in
primary breast cancer, it is our opinion that adjuvant
systemic (re-)treatment should be considered in patients
with unfavourable prognostic factors. Local recurrence
at or near the site of the original tumour [22,24–26], skin
involvement [22,27], diffuse growth of recurrence [22,24],
a short disease-free interval [3,4,8,12,13,15,20,28–30]
and an unfavourable initial tumour stage [22,31] have
been found to be predictors of a poorer prognosis in
more than one study. Patients with a recurrence remote
from the primary tumour appear to have a better prog-
nosis than those with a recurrence at or near the site of
the primary tumour [22,24–26]. The most likely explana-
tion for this finding is that the first group consists largely
of new primary tumours, whereas the recurrences that
are located at or near the site of the primary tumour
are true recurrences, originating from tumour tissue
not removed by the primary excision. In the literature
on the subject of local recurrence, the entities new pri-
mary tumour and true recurrence play an important
role. The distinction between a true recurrence and a
new primary is not always a clear-cut case. In most stud-
ies, the diagnosis new primary was applied when the
recurrence was located elsewhere in the breast, had a dif-ferent histology, or DNA flow cytometry converted
from an aneuploid primary to a diploid recurrence
[14,25,26]. In the search for reliable distinction between
new primary tumours and true recurrences, genetic tech-
niques have been developed [32,33]. Schlechter [33] re-
cently described a quantitative scoring system based
on so-called allele imbalance (AI) or loss of heterozygos-
ity (LOH). These DNA abnormalities, that are present
in nearly all breast cancers, are traceable in archival
specimens. They concluded that their approach is a
potentially valuable tool in distinguishing new primary
cancer from true recurrent disease, but further testing
with a larger sample size is necessary to draw conclu-
sions about the potential prognostic and therapeutic va-
lue of this technique.
In many studies, patients with a local recurrence
within two or three years after the original treatment ap-
peared to have a poorer overall and distant disease-free
survival compared to those with a local recurrence
occurring later [3,4,8,12,13,15,20,28–30]. True recur-
rences tend to have a shorter interval from BCT than
the recurrences that are considered to be new primary
tumours. This may explain why the proportion of pa-
tients with new primary tumours is generally larger in
studies with longer follow-up after BCT and why the
late recurrences are reported to have a better prognosis
than the early recurrences. In our study the prognosis
for patients with a local recurrence more than two years
after BCT was similar to that for patients with a local
recurrence within two years, which is in agreement with
some other studies [31,34]. The number of patients with
a recurrence more than five years after BCT was too
small to estimate their prognosis accurately.
Hardly any study is available that performed a review
of the histology slides of the local recurrence to identify
prognostic factors [30,35]. In a series of 38 patients,
DNA ploidy and S-phase fraction as measured by
flow-cytometry techniques, showed some promising re-
sults as a tool in determining prognosis [35]. In another
study of 68 patients, a high mitotic count was found to
be associated with a higher risk of distant metastases [30].
Overall and distant recurrence-free survival and local
control of disease were very poor for patients with recur-
rence in the skin of the breast, which was in accordance
with the findings of Gage [27]. Such recurrences are likely
to be markers of the metastatic potential of the tumour.
Although the 25 patients with a purely non-invasive
local recurrence had a much better prognosis than the
225 with an invasive recurrence, distant metastases oc-
curred in four of them. This is high risk when compared
to patients with primary non-invasive breast cancer and
suggests that the force of mortality remains present from
the primary invasive cancer. In contrast to patients with
invasive recurrences all distant metastases became
clinically apparent more than four years after diagnosis
of the local recurrence.
A.C. Voogd et al. / European Journal of Cancer 41 (2005) 2637–2644 2643Finally, the prognosis of patients with a local recur-
rence also tends to be related to the risk of local recur-
rence as such. This observation comes from the
patients undergoing breast-conserving surgery without
radiotherapy; the high risk of local recurrence within
this group is accompanied with a significantly better
breast-cancer-specific survival following the diagnosis
of local recurrence compared to the patients with local
recurrence following breast-conserving surgery with
radiotherapy [3].
In our large and unselected series of patients with local
recurrence following conservative surgery and radiother-
apy, long-term prognosis was poor, with a 10-year distant
disease-free survival of only 36%. Lymph node status at
the time of diagnosis of the primary tumour and location
and size of breast cancer recurrence are predictors of this
outcome.Although the latter finding suggests that follow-
updirected at early detection of local recurrencesmight be
worthwhile, it would require a large randomised study,
comparing follow-up strategies with differing intensities,
to confirm this.Conflict of interest
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